ArticleNature2025
Design of highly functional genome editors by modelling CRISPR-Cas sequences.
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed.
- Machine-learning in optimization of CRISPR technology.Machine learning. Health · 2026Review
- Challenges and Future Directives of Synthetic Biology in Engineering Plant-Microbe Partnerships for Sustainable Agriculture.Biotechnology and bioengineering · 2026Review
- Structure-guided discovery and engineering of miniature CRISPR-Cas12m for epigenome editing.Nature structural & molecular biology · 2026Article
- Article
- AI-designed OpenCRISPR-1 enables efficient targeted mutagenesis and prime editing in rice.aBIOTECH · 2026Article
- AI-designed OpenCRISPR-1 performs robust knockout, base editing, and prime editing in rice.The New phytologist · 2026Article
- Cucurbit Leaf Crumple Virus: An Important Pathogen of Cucurbit and Snap Bean Crops.Molecular plant pathology · 2026Review
- Adaptive model-guided protein evolution with sparse data optimizes compact eukaryotic genome editors.Nature biotechnology · 2026Article
- On-target and off-target activities of CRISPR therapeutics across scales.Trends in biotechnology · 2026Review
- Chemical and Structural Engineering of Guide RNAs for Precision Genome Editing: From Design Principles to Clinical Applications.Chemical biology & drug design · 2026Review
- Discovery and protein language model-guided design of hyperactive transposases.Nature biotechnology · 2026Article
- Article
- Property guidance for protein sequence generative models with ProteinGuide.Nature biotechnology · 2026Article
- Structure-guided engineering of AI-derived adenine base editors for nuclear and mitochondrial DNA editing.Nucleic acids research · 2026Article
- Structure and evolution-guided design of minimal RNA-guided nucleases.Science (New York, N.Y.) · 2026Article
- Article
- AI-orchestrated design-build-test-learn is the future of mammalian biodesign.Nature biomedical engineering · 2026Article
- Artificial intelligence in biologic drug discovery: A review of methodological evolution and therapeutic applications.Acta pharmaceutica Sinica. B · 2026Review
- Harnessing artificial intelligence in plant breeding: innovations in digital phenotyping and breeding methodologies.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2026Review
- Insights from adaptive immune regulation for disease resistance breeding in livestock and poultry.Science China. Life sciences · 2026Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene editing has the potential to solve fundamental challenges in agriculture, biotechnology and human health. CRISPR-based gene editors derived from microorganisms, although powerful, often show notable functional tradeoffs when ported into non-native environments, such as human cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.